earnings
confidence high
sentiment neutral
materiality 0.65
iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%
iBio, Inc.
2026-Q3 EPS reported
-$0.25
revenue$100,000
- No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).
- Cash, cash equivalents, and investments in debt securities $74.8M as of March 31, 2026; additional $17M from warrant exercises in Q4, extending cash runway into Q4 FY2028.
- Received regulatory clearance from Australia's TGA and HREC to initiate Phase 1 trial of IBIO-600 (anti-myostatin antibody) in overweight/obese adults; first dosing expected Q2 calendar 2026.
- Announced pipeline expansion into PH-HFpEF with a selective bispecific antibody blocking Activin A, GDF8, GDF11 to reduce cardiac fibrosis and vascular remodeling.
- Preclinical NHP data for IBIO-610: after two doses, visceral fat reduced by 6.7%, total fat mass by 5.2% (small, not statistically powered study).